1091 related articles for article (PubMed ID: 26883272)
1. Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non-Small Cell Lung Cancer.
Jang JY; Kim YG; Nam SJ; Keam B; Kim TM; Jeon YK; Kim CW
Mol Cancer Ther; 2016 Jun; 15(6):1387-96. PubMed ID: 26883272
[TBL] [Abstract][Full Text] [Related]
2. MicroRNA-214 regulates the acquired resistance to gefitinib via the PTEN/AKT pathway in EGFR-mutant cell lines.
Wang YS; Wang YH; Xia HP; Zhou SW; Schmid-Bindert G; Zhou CC
Asian Pac J Cancer Prev; 2012; 13(1):255-60. PubMed ID: 22502680
[TBL] [Abstract][Full Text] [Related]
3. Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: the effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab.
Chen G; Kronenberger P; Teugels E; Umelo IA; De Grève J
BMC Med; 2012 Mar; 10():28. PubMed ID: 22436374
[TBL] [Abstract][Full Text] [Related]
4. YES1 as a potential target to overcome drug resistance in EGFR-deregulated non-small cell lung cancer.
Kook E; Lee J; Kim DH
Arch Toxicol; 2024 May; 98(5):1437-1455. PubMed ID: 38443724
[TBL] [Abstract][Full Text] [Related]
5. Molecular mechanism of the schedule-dependent synergistic interaction in EGFR-mutant non-small cell lung cancer cell lines treated with paclitaxel and gefitinib.
Cheng H; An SJ; Dong S; Zhang YF; Zhang XC; Chen ZH; Jian-Su ; Wu YL
J Hematol Oncol; 2011 Jan; 4():5. PubMed ID: 21255411
[TBL] [Abstract][Full Text] [Related]
6. Knockdown of the Bcl-2 gene increases sensitivity to EGFR tyrosine kinase inhibitors in the H1975 lung cancer cell line harboring T790M mutation.
Zou M; Xia S; Zhuang L; Han N; Chu Q; Chao T; Peng P; Chen Y; Gui Q; Yu S
Int J Oncol; 2013 Jun; 42(6):2094-102. PubMed ID: 23588221
[TBL] [Abstract][Full Text] [Related]
7. Enhanced Sensitivity of Nonsmall Cell Lung Cancer with Acquired Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors to Phenformin: The Roles of a Metabolic Shift to Oxidative Phosphorylation and Redox Balance.
Kim S; Im JH; Kim WK; Choi YJ; Lee JY; Kim SK; Kim SJ; Kwon SW; Kang KW
Oxid Med Cell Longev; 2021; 2021():5428364. PubMed ID: 34367462
[TBL] [Abstract][Full Text] [Related]
8. Epidermal growth factor signals regulate dihydropyrimidine dehydrogenase expression in EGFR-mutated non-small-cell lung cancer.
Tominaga T; Tsuchiya T; Mochinaga K; Arai J; Yamasaki N; Matsumoto K; Miyazaki T; Nagasaki T; Nanashima A; Tsukamoto K; Nagayasu T
BMC Cancer; 2016 Jun; 16():354. PubMed ID: 27268079
[TBL] [Abstract][Full Text] [Related]
9. Melatonin sensitizes H1975 non-small-cell lung cancer cells harboring a T790M-targeted epidermal growth factor receptor mutation to the tyrosine kinase inhibitor gefitinib.
Yun M; Kim EO; Lee D; Kim JH; Kim J; Lee H; Lee J; Kim SH
Cell Physiol Biochem; 2014; 34(3):865-72. PubMed ID: 25199820
[TBL] [Abstract][Full Text] [Related]
10. Gefitinib inhibits invasive phenotype and epithelial-mesenchymal transition in drug-resistant NSCLC cells with MET amplification.
La Monica S; Caffarra C; Saccani F; Galvani E; Galetti M; Fumarola C; Bonelli M; Cavazzoni A; Cretella D; Sirangelo R; Gatti R; Tiseo M; Ardizzoni A; Giovannetti E; Petronini PG; Alfieri RR
PLoS One; 2013; 8(10):e78656. PubMed ID: 24167634
[TBL] [Abstract][Full Text] [Related]
11. JUN-Mediated Downregulation of EGFR Signaling Is Associated with Resistance to Gefitinib in EGFR-mutant NSCLC Cell Lines.
Kani K; Garri C; Tiemann K; Malihi PD; Punj V; Nguyen AL; Lee J; Hughes LD; Alvarez RM; Wood DM; Joo AY; Katz JE; Agus DB; Mallick P
Mol Cancer Ther; 2017 Aug; 16(8):1645-1657. PubMed ID: 28566434
[TBL] [Abstract][Full Text] [Related]
12. Hypoxia induces gefitinib resistance in non-small-cell lung cancer with both mutant and wild-type epidermal growth factor receptors.
Minakata K; Takahashi F; Nara T; Hashimoto M; Tajima K; Murakami A; Nurwidya F; Yae S; Koizumi F; Moriyama H; Seyama K; Nishio K; Takahashi K
Cancer Sci; 2012 Nov; 103(11):1946-54. PubMed ID: 22863020
[TBL] [Abstract][Full Text] [Related]
13. miR-138-5p reverses gefitinib resistance in non-small cell lung cancer cells via negatively regulating G protein-coupled receptor 124.
Gao Y; Fan X; Li W; Ping W; Deng Y; Fu X
Biochem Biophys Res Commun; 2014 Mar; 446(1):179-86. PubMed ID: 24582749
[TBL] [Abstract][Full Text] [Related]
14. β-Catenin overexpression is associated with gefitinib resistance in non-small cell lung cancer cells.
Fang X; Gu P; Zhou C; Liang A; Ren S; Liu F; Zeng Y; Wu Y; Zhao Y; Huang B; Zhang Z; Yi X
Pulm Pharmacol Ther; 2014 Jun; 28(1):41-48. PubMed ID: 23707949
[TBL] [Abstract][Full Text] [Related]
15. The Impact of Inadequate Exposure to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors on the Development of Resistance in Non-Small-Cell Lung Cancer Cells.
Frezzetti D; Caridi V; Marra L; Camerlingo R; D'Alessio A; Russo F; Dotolo S; Rachiglio AM; Esposito Abate R; Gallo M; Maiello MR; Morabito A; Normanno N; De Luca A
Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38732063
[TBL] [Abstract][Full Text] [Related]
16. Hypoxia increases gefitinib-resistant lung cancer stem cells through the activation of insulin-like growth factor 1 receptor.
Murakami A; Takahashi F; Nurwidya F; Kobayashi I; Minakata K; Hashimoto M; Nara T; Kato M; Tajima K; Shimada N; Iwakami S; Moriyama M; Moriyama H; Koizumi F; Takahashi K
PLoS One; 2014; 9(1):e86459. PubMed ID: 24489728
[TBL] [Abstract][Full Text] [Related]
17. Curcumin overcome primary gefitinib resistance in non-small-cell lung cancer cells through inducing autophagy-related cell death.
Chen P; Huang HP; Wang Y; Jin J; Long WG; Chen K; Zhao XH; Chen CG; Li J
J Exp Clin Cancer Res; 2019 Jun; 38(1):254. PubMed ID: 31196210
[TBL] [Abstract][Full Text] [Related]
18. PLAUR Confers Resistance to Gefitinib Through EGFR/P-AKT/Survivin Signaling Pathway.
Zhou J; Kwak KJ; Wu Z; Yang D; Li J; Chang M; Song Y; Zeng H; Lee LJ; Hu J; Bai C
Cell Physiol Biochem; 2018; 47(5):1909-1924. PubMed ID: 29961070
[TBL] [Abstract][Full Text] [Related]
19. Chronic treatment of non-small-cell lung cancer cells with gefitinib leads to an epigenetic loss of epithelial properties associated with reductions in microRNA-155 and -200c.
Narita M; Shimura E; Nagasawa A; Aiuchi T; Suda Y; Hamada Y; Ikegami D; Iwasawa C; Arakawa K; Igarashi K; Kuzumaki N; Yoshioka Y; Ochiya T; Takeshima H; Ushijima T; Narita M
PLoS One; 2017; 12(2):e0172115. PubMed ID: 28225782
[TBL] [Abstract][Full Text] [Related]
20. [FOXC1 Knockdown Reverses Gefitinib Resistance in Non-small Cell Lung Cancer].
Peng C; Li P; Yang M; Chen D; Huang Y
Zhongguo Fei Ai Za Zhi; 2021 Aug; 24(8):538-547. PubMed ID: 34334155
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
